Spyre Therapeutics, Inc.
HealthcareNASDAQ:SYRE · NASDAQ Capital Market
+$0.02 today
Vol 0.79M · Avg 1.16M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$90.5M of revenue converted into -$179.4M of net income for the selected period. Gross margin is 12.5% and net margin is -17.3%, showing how much revenue survives after costs and taxes. EPS is $-2.19, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 -100.0% | $886.0K -62.0% | $2.3M -87.6% | $18.7M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $171.7M | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$171.7M | $0 -100.0% | $886.0K -62.0% | $2.3M -87.6% | $18.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $171.7M +5.4% | $162.8M +81.9% | $89.5M +52.8% | $58.6M +2.6% | $57.1M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $47.9M +4.7% | $45.8M +14.6% | $39.9M +40.0% | $28.5M +4.4% | $27.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $37.9M -81.8% | $208.6M -14.2% | $243.2M +179.2% | $87.1M +3.2% | $84.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $10.0M | $0 -100.0% | $964.0K -50.9% | $2.0M +24.6% | $1.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$209.6M -0.8% | -$208.0M -63.0% | -$127.6M -55.6% | -$82.0M -27.9% | -$64.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | -14401.8% -10881.5pp | -3520.3% -3178.3pp | -342.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$209.6M -0.5% | -$208.6M +13.9% | -$242.3M -185.8% | -$84.8M -29.1% | -$65.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | -27348.0% -23707.7pp | -3640.2% -3289.9pp | -350.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $24.9M +16.8% | $21.3M +246.7% | $6.1M +634.4% | $837.0K +654.1% | $111.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $54.3M +8972.5% | $599.0K +100.6% | -$96.5M -11728.1% | $830.0K +7645.5% | -$11.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$155.2M +25.4% | -$208.0M +38.6% | -$338.8M -303.6% | -$84.0M -27.9% | -$65.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | -38241.1% -34636.5pp | -3604.6% -3254.2pp | -350.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$15.0K -129.4% | $51.0K +296.2% | -$26.0K +80.9% | -$136.0K -196.5% | $141.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$155.2M +25.4% | -$208.0M +38.6% | -$338.8M -304.2% | -$83.8M -27.4% | -$65.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | -38238.1% -34639.4pp | -3598.8% -3247.6pp | -351.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +37.7% | -$3 +93.1% | -$46 -85.6% | -$25 +0.6% | -$25 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +37.7% | -$3 +93.1% | -$46 -85.6% | -$25 +0.6% | -$25 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $346.0M +635.8% | $47.0M +581.9% | $6.9M +104.6% | $3.4M +28.2% | $2.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $346.0M +635.8% | $47.0M +581.9% | $6.9M +104.6% | $3.4M +28.2% | $2.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Pharvaris N.V.
NASDAQ:PHVS
$2.15B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.08B
Immunome, Inc.
NASDAQ:IMNM
$1.76B
Zymeworks Inc.
NASDAQ:ZYME
$1.68B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.60B
Ardelyx, Inc.
NASDAQ:ARDX
$1.41B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.36B
Maze Therapeutics, Inc.
NASDAQ:MAZE
$1.33B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.13B
Upstream Bio, Inc.
UPB
$331.96M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SYRE generate?
Spyre Therapeutics, Inc. (SYRE) reported $0.00 of revenue in fiscal 2025.
Is SYRE profitable?
Spyre Therapeutics, Inc. (SYRE) reported -$155,203,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.